title: Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.
abstract: Few therapeutic options are available for T790M-negative non-small cell lung cancer (NSCLC) after failure of primary epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy. This report presents the case of a 71-year-old Asian female never smoker with EGFR mutated T790M negative non squamous cell lung cancer (NSCLC) pre-treated with the experimental epi-immunotherapeutic agent, RRx-001, that re-responded to single agent carboplatin after failure of platinum doublets, TKIs, pemetrexed and nivolumab. The management of advanced EGFR mutation-positive NSCLC is briefly reviewed herein and the emerging paradigm of episensitization, which contradicts the long-standing and widely accepted tenet about the immutability of resistance and the futility of therapeutic rechallenge, is introduced as a strategy to avert treatment failure and thereby stave off deterioration and death.
authors.affiliation: Walter Reed National Military Medical Center, Murtha Cancer Center, 8901 Wisconsin Ave, Bethesda, MD 20889, USA.
authors.forename: Corey A
authors.initials: CA
authors.lastname: Carter
authors.affiliation: EpicentRx, Inc., 800 W El Camino Real, Suite 180, Mountain View, CA 94040, USA.
authors.forename: Bryan
authors.initials: B
authors.lastname: Oronsky
authors.affiliation: EpicentRx, Inc., 800 W El Camino Real, Suite 180, Mountain View, CA 94040, USA.
authors.forename: Scott
authors.initials: S
authors.lastname: Caroen
authors.affiliation: EpicentRx, Inc., 800 W El Camino Real, Suite 180, Mountain View, CA 94040, USA.
authors.forename: Jan
authors.initials: J
authors.lastname: Scicinski
authors.affiliation: University of California San Diego, Dept of Bioengineering, 9500 Gilman Dr, La Jolla, CA 92093, USA.
authors.forename: Pedro
authors.initials: P
authors.lastname: Cabrales
authors.affiliation: Walter Reed National Military Medical Center, Murtha Cancer Center, 8901 Wisconsin Ave, Bethesda, MD 20889, USA.
authors.forename: Aiste
authors.initials: A
authors.lastname: Degesys
authors.affiliation: Walter Reed National Military Medical Center, Murtha Cancer Center, 8901 Wisconsin Ave, Bethesda, MD 20889, USA.
authors.forename: Christina
authors.initials: C
authors.lastname: Brzezniak
keywords: EGFR; Episensitization; NSCLC; RRx-001; T790 mutation